Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Light study of Contrave experiences accelerated enrollment

Sep. 6, 2012

Novel monoclonal antibodies patented by IRM and Novartis

Sep. 6, 2012

BioSante Pharmaceuticals reports phase III safety data for LibiGel

Sep. 5, 2012

Stem cell gene therapy improves erectile dysfunction in rats

Sep. 5, 2012

New series of GPR119 agonists optimized by Bristol-Myers Squibb

Sep. 4, 2012

Silodosin evaluated for premature ejaculation

Sep. 4, 2012

Novo Nordisk gives update on approval of insulin degludec in Japan

Sep. 3, 2012

Bristol-Myers Squibb profiles novel MCH1 receptor antagonist

Sep. 3, 2012

Mechanism of action of epelsiban besilate further elucidated

Sep. 3, 2012

CB2 receptor agonist proves useful for the treatment of erectile dysfunction

Sep. 3, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...